Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Humans
Mycobacterium tuberculosis
Antitubercular Agents
/ pharmacology
Isoniazid
/ pharmacology
Pyrazinamide
/ therapeutic use
Rifampin
/ therapeutic use
Linezolid
/ pharmacology
Amikacin
/ pharmacology
Moxifloxacin
/ therapeutic use
Tuberculosis, Multidrug-Resistant
/ epidemiology
Microbial Sensitivity Tests
Verapamil
/ pharmacology
Mutation
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
10
2022
accepted:
08
10
2023
medline:
30
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Tuberculosis stands as a prominent cause of mortality in developing countries. The treatment of tuberculosis involves a complex procedure requiring the administration of a panel of at least four antimicrobial drugs for the duration of six months. The occurrence of treatment failure after the completion of a standard treatment course presents a serious medical problem. The purpose of this study was to evaluate antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. Additionally, it aimed to evaluate the effectiveness of second line drugs such as amikacin, linezolid, moxifloxacin, and the efflux pump inhibitor verapamil against M. tuberculosis isolates associated with treatment failure. We monitored 1200 tuberculosis patients who visited TB centres in Lahore and found that 64 of them were not cured after six months of treatment. Among the M. tuberculosis isolates recovered from the sputum of these 64 patients, 46 (71.9%) isolates were simultaneously resistant to rifampicin and isoniazid (MDR), and 30 (46.9%) isolates were resistant to pyrazinamide, Resistance to amikacin was detected in 17 (26,5%) isolates whereas resistance to moxifloxacin and linezolid was detected in 1 (1.5%) and 2 (3.1%) isolates respectively. Among MDR isolates, the additional resistance to pyrazinamide, amikacin, and linezolid was detected in 15(23.4%), 4(2.6%) and 1(1.56%) isolates respectively. One isolate simultaneously resistant to rifampicin, isoniazid, amikacin, pyrazinamide, and linezolid was also identified. In our investigations, the most frequently mutated amino acid in the treatment failure group was Serine 315 in katG. Three novel mutations were detected at codons 99, 149 and 154 in pncA which were associated with pyrazinamide resistance. The effect of verapamil on the minimum inhibitory concentration of isoniazid and rifampicin was observed in drug susceptible isolates but not in drug resistant isolates. Rifampicin and isoniazid enhanced the transcription of the efflux pump gene rv1258 in drug susceptible isolates collected from the treatment failure patients. Our findings emphasize a high prevalence of MDR isolates linked primarily to drug exposure. Moreover, the use of amikacin as a second line drug may not be the most suitable choice in such cases.
Identifiants
pubmed: 37883448
doi: 10.1371/journal.pone.0293194
pii: PONE-D-22-27870
pmc: PMC10602240
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Pyrazinamide
2KNI5N06TI
Rifampin
VJT6J7R4TR
Linezolid
ISQ9I6J12J
Amikacin
84319SGC3C
Moxifloxacin
U188XYD42P
Verapamil
CJ0O37KU29
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293194Informations de copyright
Copyright: © 2023 Mushtaq et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Microbiol. 2017 Sep;55(9):2736-2751
pubmed: 28659320
Cell Host Microbe. 2007 Nov 15;2(5):352-64
pubmed: 18005756
Infect Genet Evol. 2016 Nov;45:474-492
pubmed: 27612406
J Intern Med. 2012 Dec;272(6):541-61
pubmed: 23025745
Tuberc Res Treat. 2013;2013:108401
pubmed: 23606961
Future Microbiol. 2019 Feb;14:185-194
pubmed: 30648892
J Exp Med. 2003 Sep 1;198(5):693-704
pubmed: 12953091
Emerg Infect Dis. 2012 Apr;18(4):653-5
pubmed: 22469053
J Antimicrob Chemother. 2003 Nov;52(5):790-5
pubmed: 14563891
Nat Commun. 2020 Aug 7;11(1):3970
pubmed: 32769975
Clin Microbiol Rev. 2006 Apr;19(2):382-402
pubmed: 16614254
J Infect Chemother. 2021 Nov;27(11):1578-1583
pubmed: 34244055
J Clin Microbiol. 2006 Mar;44(3):688-92
pubmed: 16517840
Int J Infect Dis. 2017 Mar;56:181-184
pubmed: 27818361
Lancet. 2021 Oct 30;398(10311):1593-1618
pubmed: 34755628
BMC Microbiol. 2014 Jun 22;14:165
pubmed: 24953243
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Electrophoresis. 1997 Dec;18(15):2714-23
pubmed: 9504803
Microbiology (Reading). 2013 Oct;159(Pt 10):2049-2057
pubmed: 23918818
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29463541
Infect Drug Resist. 2021 Oct 05;14:4119-4128
pubmed: 34675557
Future Microbiol. 2019 Apr;14:533-552
pubmed: 31066586
FEMS Microbiol Rev. 2022 Feb 9;46(1):
pubmed: 34637511
3 Biotech. 2016 Jun;6(1):108
pubmed: 28330178
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30602521
Mol Microbiol. 2010 Apr;76(2):348-64
pubmed: 20233304
Trends Microbiol. 2022 Jan;30(1):57-68
pubmed: 34052094
Front Microbiol. 2019 Feb 19;10:216
pubmed: 30837962
Front Microbiol. 2018 Dec 13;9:3072
pubmed: 30619157
Microb Drug Resist. 2020 Aug;26(8):971-975
pubmed: 32101083
Int J Mycobacteriol. 2014 Sep;3(3):173-7
pubmed: 26786485
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Apr 12;43(4):356-361
pubmed: 32294818
Lancet Microbe. 2022 Apr;3(4):e265-e273
pubmed: 35373160
Antimicrob Agents Chemother. 2014;58(1):574-6
pubmed: 24126586
J Infect Dis. 2019 Apr 19;219(10):1554-1558
pubmed: 30753612